Potential new drug target to combat Kaposi's sarcoma

May 6, 2010

Research from the University of Leeds has identified how the virus which causes Kaposi's Sarcoma replicates and spreads - opening a door to a possible new treatment for the disease.

Kaposi's Sarcoma is a cancer caused by a human herpes virus and is widespread in sub-Saharan Africa, where it is the most common cause of cancer amongst those infected with HIV.

Researchers from Leeds' Faculty of Biological Sciences found that a human protein - known as PYM - is hijacked by the virus to help it replicate. A virus-encoded protein, ORF57, interacts with PYM and when this interaction was blocked during molecular experiments, the virus was unable to replicate. The findings are published today in the .

"This is the first time that the , PYM, has been shown to play a role in and Kaposi's Sarcoma," explains Dr Adrian Whitehouse, who led the research. "Our work is still at a very early stage, but it should in time be possible to design drugs which block the interaction between PYM and the , thereby stopping the virus replicating and hopefully stopping the cancer from developing."

Kaposi's Sarcoma-associated herpesvirus is an opportunistic infection which is most prevalent amongst people with a weakened immune system, such as those infected with HIV. Treatment for KS does exist but currently involves chemotherapy and highly which is both toxic and not always effective. Moreover, such combined therapies are only available to a small percentage of those affected in sub-Saharan Africa and other parts of the developing world.

The researchers - funded by the Wellcome Trust and BBSRC - are now looking to obtain the structure of these two interacting proteins, as the next step towards designing an anti-viral drug to combat the disease.

Explore further: Major Kaposi's sarcoma discovery announced

Related Stories

Penn researchers discover new mechanism for viral replication

August 16, 2007

Researchers at the University of Pennsylvania School of Medicine have identified a new strategy that Kaposi’s Sarcoma Associated Herpesvirus (KSHV) uses to dupe infected cells into replicating its viral genome. This allows ...

DNA damage response confers a barrier for viral tumorigenesis

September 28, 2007

Kaposi’s sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi’s sarcoma (KS). KSHV infection is endemic in sub-Saharan Africa where KS is nowadays the most common malignancy, due to widespread ...

Scientists tackle viral mysteries

June 29, 2009

Scientists know that some cancers are triggered by viruses, which take over cellular systems and cause uncontrolled cell growth. Doctors - and patients who get shingles late in life - have also known for many years that ...

Researchers identify new drug target for Kaposi's sarcoma

July 30, 2009

UCSF researchers have identified a new potential drug target for the herpes virus that causes Kaposi's sarcoma, re-opening the possibility of using the class of drugs called protease inhibitors against the full herpes family ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.